# To Demonstrate the Relative Bioavailability Study of Ondansetron HCl 24 mg Tablets Under Non-Fasting Conditions

> **NCT00947128** · PHASE1 · COMPLETED · sponsor: **Sandoz** · enrollment: 26 (actual)

## Conditions studied

- Nausea
- Vomiting

## Interventions

- **DRUG:** Ondansetron HCl 24 mg Tablets (Sandoz, Inc.)
- **DRUG:** Zofran (Ondansetron HCl) 24 mg Tablets (GlaxoSmithKline)

## Key facts

- **NCT ID:** NCT00947128
- **Lead sponsor:** Sandoz
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-09
- **Primary completion:** 2004-10
- **Final completion:** 2004-10
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2017-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00947128

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00947128, "To Demonstrate the Relative Bioavailability Study of Ondansetron HCl 24 mg Tablets Under Non-Fasting Conditions". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00947128. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*